Last updated: April 23, 2026
Which companies supply methotrexate APIs (and what formats are typically available)?
Methotrexate is a widely manufactured oncology/autoimmune API. Suppliers typically sell one or more of these product types: (1) methotrexate API, (2) methotrexate active in sterile or dose-ready forms via contract manufacturing, and (3) key intermediates used in API manufacture (less consistently disclosed in public data).
Below are documented supplier positions from major procurement and regulatory-facing marketplaces that track drug master files, product catalogs, or “active ingredient” listings.
Methotrexate API suppliers (publicly listed)
| Supplier |
Product type shown in listings |
What is offered (as listed) |
Where it shows up |
| Mylan / Viatris |
API and/or finished products are sold through global channels |
Methotrexate products are included in company portfolios and market catalogs |
Company/market listings tracking methotrexate supply |
| Teva |
Finished dosage and/or API supply channels |
Methotrexate is included in oncology/immune portfolio |
Company/market listings |
| Dr. Reddy’s Laboratories |
API/finished product supply presence |
Methotrexate is included in market portfolios |
Company/market listings |
| Sandoz (Novartis) |
Finished dosage supply presence |
Methotrexate is included in portfolio listings |
Company/market listings |
| Hospira/Pfizer legacy channels |
Finished dosage availability |
Methotrexate products are distributed through legacy and successor portfolios |
Distribution and market listings |
Limitations of public listings: public supplier catalogs often list “methotrexate” without publishing compliance details (DMF status, CEP/DMF numbers, grade, or sterility assurance). For R&D or commercialization decisions, procurement teams should map each candidate supplier to the regulatory dossier path used for the target market (DMF, CEP, or API written confirmation).
Which suppliers provide methotrexate through contract manufacturing for finished dosage forms?
For finished dosage products, methotrexate is typically supplied via:
1) innovator/large branded manufacturers,
2) established generics companies with in-house or partnered manufacturing, and
3) contract manufacturing organizations (CMOs) that support sterile injectables or oral tablets depending on the dosage form.
Public-facing procurement databases often list methotrexate under generic/finished dosage availability rather than named CMOs. What is more consistently searchable in procurement is finished dosage supply by manufacturer label, not the underlying CMO.
Finished dosage suppliers commonly listed
| Manufacturer label (supplier to market) |
Dosage form commonly seen in listings |
Market presence |
| Teva |
tablets and injections |
broad global |
| Sandoz |
tablets and injections |
broad global |
| Dr. Reddy’s |
tablets and injections |
broad global |
| Mylan / Viatris |
tablets and injections |
broad global |
| Hospira/Pfizer legacy |
injections |
legacy and successor supply chains |
(These manufacturers are repeatedly listed in market catalogs and regulatory-facing product databases that track methotrexate availability.)
Who supplies methotrexate intermediates (and why does it matter for sourcing risk)?
Methotrexate is synthesized through established chemical routes with multiple critical intermediates. In practice, procurement risk concentrates on:
- stability of key intermediates,
- control of impurities (including process-related and genotoxic impurities where applicable),
- batch-to-batch traceability and compliance documentation.
Public supplier lists for intermediates are less consistent than API or finished dosage listings; many intermediary suppliers sell into API manufacturers under confidentiality. As a result, most sourcing strategies treat intermediates as a vendor qualification overlay on top of the API supplier’s disclosed synthesis route.
What vendor categories should you use for methotrexate sourcing?
For commercial and development sourcing, methotrexate procurement usually fits into three tracks:
1) API supplier qualification track
- API grade aligned to intended dosage form
- compliance documentation for target markets
2) Dosage form outsourcing track
- sterile vs non-sterile distinction
- packaging, labeling, stability plan support
3) Regulatory documentation track
- DMF path (US) and/or CEP path (EU)
- batch release testing package alignment
This segmentation matters because methotrexate’s product risk differs by dosage form: sterile injections create higher requirements for aseptic process control and microbial/bioburden testing.
How to short-list suppliers for methotrexate (procurement filters that match typical regulatory expectations)
Public listings alone do not identify whether a supplier can support a dossier-ready supply chain. A procurement short-list should be built around documentation and quality artifacts typically requested during vendor qualification.
Core qualification artifacts to demand during supplier selection
- Certificate of Analysis (CoA) templates by batch type
- impurity profile / specification set (including limits and analytical methods)
- stability commitment (formal stability plan for final dosage or API as applicable)
- change control history and notification process
- GMP status evidence for manufacturing site(s)
- audit readiness and material traceability
These filters align with how major generic and branded manufacturers manage API sourcing risk and batch release governance in regulated supply chains.
Supplier sourcing channels that most often succeed for methotrexate
Methotrexate procurement most commonly goes through one or more of the following channels:
- Direct from established generics/large pharma supplier programs (for APIs and/or finished products).
- Procurement brokers and API distributors (for earlier stage availability and fast lead times).
- Direct from API manufacturers with DMF/CEP documentation on file (for dossier-aligned supply).
Brokers can reduce time-to-supply but usually require tighter documentation control to avoid gaps in compliance packets.
Reference points for validation: where methotrexate supply and documentation are tracked
For supplier selection and verification, teams typically validate supplier claims via external listings and regulatory tracking platforms that maintain product and manufacturer visibility.
Regulatory and market visibility sources
- U.S. FDA Orange Book (finished dosage product listings and applicant/manufacturer visibility) for mapping who is selling methotrexate products under ANDA/market authorizations.
Source: FDA Orange Book. [1]
- FDA’s Drug Shortages database for availability disruptions that often correlate with supplier constraints.
Source: FDA Drug Shortages. [2]
- European and other regional regulatory product databases used in parallel for CEP and dossier mapping.
Practical supplier selection outcomes for methotrexate
Given methotrexate’s long history and broad market presence, the supplier set is stable across time but can shift with:
- injection supply constraints during facility remediation,
- API impurity control updates,
- site ownership changes and product discontinuations.
Procurement teams typically maintain a 2-supplier strategy for active risk coverage, with one “primary” and one “backup” supplier qualified under the same specification and documentation framework.
Key Takeaways
- Methotrexate sourcing is dominated by large generics and established API suppliers, with market visibility most reliably captured through finished product listings (Orange Book) and supplier/portfolio catalogs.
- The fastest path to credible supply usually comes from vendors that can map documentation to the intended regulatory pathway (DMF/CEP) rather than from raw catalog availability.
- Sterile injection forms create higher qualification load than oral tablets, so supplier selection filters should reflect aseptic and quality system maturity.
FAQs
1) Who are the most visible methotrexate suppliers in regulated markets?
Teva, Sandoz, Dr. Reddy’s Laboratories, and Mylan/Viatris show as prominent suppliers through product portfolio and regulated market listings. [1]
2) Where can I verify methotrexate product manufacturers and applicants?
The U.S. FDA Orange Book lists approved methotrexate products by applicant and manufacturer. [1]
3) How do I reduce supply disruption risk for methotrexate?
Use FDA drug shortage monitoring to identify constraints and keep at least one qualified backup supply chain. [2]
4) Are intermediates typically listed publicly by methotrexate API vendors?
Not consistently. Intermediate sourcing is often handled through confidential arrangements with API manufacturers unless vendors disclose route-related intermediate specifications in catalogs.
5) Does supplier selection differ for methotrexate injections vs tablets?
Yes. Injection sourcing requires qualification aligned with sterile manufacturing controls, while tablets generally reduce sterility-specific burden but still require impurity and stability alignment.
References
[1] U.S. Food and Drug Administration. (n.d.). FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] U.S. Food and Drug Administration. (n.d.). Drug Shortages. https://www.fda.gov/drugs/drug-shortages
